For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Need for Economic Assessment of Drugs Pointed Out at Chuikyo
November 22, 2010
- Nippon Shinyaku: Cialis Drives Sales
November 22, 2010
- Alfresa: Operating Profits More than Double
November 22, 2010
- Afinitor Approved for Brain Tumors: Novartis
November 22, 2010
- Zeria: Asacol Drives Sales, Profits
November 22, 2010
- Suzuken: Operating Loss Reported for the First Time
November 22, 2010
- Enroll Japanese Patients in Early-Stage Global Studies
November 22, 2010
- Fuso: Generics Make Up for Decreases in Sales
November 22, 2010
- Toho: Sales Up 9.1% Boosted by Addition of SAYWELL
November 22, 2010
- EFPIA Survey Shows “Over-Quality” of Clinical Trials in Japan
November 22, 2010
- Torii: New Products Drive Sales
November 22, 2010
- VITAL KSK: Sales Remain Virtually Flat
November 22, 2010
- Takeda Enters into CNS Research Alliance with Sage Bionetworks
November 22, 2010
- ASKA: Sales Up 45.7% Driven by SELTOUCH
November 22, 2010
- HOKUYAKU TAKEYAMA: Operating Profits for Pharma. Business Down 14.8%
November 22, 2010
- Pfizer to Apply for Crizotinib in 1st Half of 2011
November 22, 2010
- Seikagaku: Strong Domestic Sales Offset Weak Overseas Sales
November 22, 2010
- MSD Transfers 6 Long-Listed Products to Nichi-Iko
November 22, 2010
- Eisai Reports Positive PIII Results in Obese T2D Patients
November 22, 2010
- JCR: Agreement with GSK Props Up Business
November 22, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…